Good MorningEquity markets will open near an all-time high following the Juneteenth holiday and will likely continue higher over the summer. The FOMC and inflation remain reasons to worry but have become a pile of bricks used to build a Wall of Worry that keeps increasing. The market is moving higher on earnings growth and will likely rally until the outlook for earnings changes, and there are only two possibilities to look forward to.
The first is a soft landing for the economy, an interest rate cut, and S&P 500 earnings stability, if not growth. The second scenario includes a hard landing, recession, and earnings contraction. In the first scenario the S&P 500 can continue to rally indefinitely, in the second a significant correction would follow. The question for investors is if the economy can sustain growth until the FOMC cuts rates or if it will reach its peak and begin to recede before they do. As it is, the first cut isn't expected until November, and it may not come then. Featured: The tallest chimney in America fell in seconds (Ad) 
|
Healthcare | |
Outlook Therapeutics (NASDAQ: OTLK) has gained attention, with analysts forecasting an upside of over 500% based on the consensus price target.
It's essential to remember that low-float biopharmaceutical companies often experience volatility due to frequent breaking news and technical factors ... Read the Full Story |
|
From Our Partners | | No president has moved markets like Trump, adding and erasing trillions in value seemingly at will.
Analyst Larry says that's only the warm-up. He points to a plan that's obsessed Trump for over a decade, one he believes could send billions into a single ticker.
See the presentation and get the ticker name before the move plays out. | | Watch the free presentation and get the ticker name now |
|
Consumer Staples | |
Global food and beverage company Campbell Soup Co. (NYSE: CPB) reported solid earnings accompanied by raised guidance, but the market continued to sell off shares. However, clues were sprinkled throughout its earnings presentation that indicate a return of growth acceleration is coming in the se... Read the Full Story |
|
Technology | |
Zebra Technologies (NASDAQ: ZBRA) stock hit bottom in 2023, but it took until this year for the reversal to be completed. Now, the stock is up 50% from the recent low and heading higher under the influence of analysts. Analysts' sentiments also bottomed during the last twelve months, and a rever... Read the Full Story |
|
From Our Partners | | On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade.
Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction.
A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | | Request the free guide in 30 seconds and get positioned now |
|
Energy | |
Oil prices (NYSEARCA: USO) are near the low end of a multi-year trading range, aiding the broad market rally in stocks. Oil prices are a fundamental driver of inflation that compounds within the economy, and the inflation outlook is driving the market. Lower oil prices undercut inflation.
The ... Read the Full Story |
|
Healthcare | |
The Alzheimer's treatment landscape presents a compelling opportunity for investors in healthcare and biotech. Alzheimer's disease is a progressive and debilitating neurodegenerative disorder that poses a significant and growing threat to global health and economic well-being. With an estimated 6.... Read the Full Story |
|
From Our Partners | | Weiss Ratings, the watchdog that has flagged major financial shifts for 55 years, is warning about a little-known government financial operation affecting retirement accounts.
Its stock ratings have historically produced returns that could have more than tripled the S&P 500's gains since 2003, a track record now focused on this emerging risk. | | Read the free report and get the Retirement Defense Kit now |
|
Finance | |
The typical advice in the financial market is to never blindly follow a whale investor like Warren Buffett. However, these investors' reverse-engineering investment decisions can often prove helpful. Today, Warren Buffett didn't buy more shares of Occidental Petroleum Co. (NYSE: OXY) because the e... Read the Full Story |
|
Industrials | |
3M (NYSE: MMM) is turning a corner. The company wasn’t hurt by ailing business so much as lawsuits related to legacy businesses that are now primarily in the past. The settlements may still be appealed or amended, but the $18-odd billion in damages is close to the final payments expected. Th... Read the Full Story |
|
Technology | |
The artificial intelligence (AI) sector is experiencing explosive growth, captivating investors and sending ripples through the stock market. Super Micro Computer (NASDAQ: SMCI) is a leading high-performance computing and AI infrastructure provider. Super Micro’s financials show that it has ... Read the Full Story |
|
Consumer Discretionary | |
VinFast Auto Ltd. (NASDAQ: VFS) is a Vietnamese manufacturer of electric vehicles (EVs), e-buses, and e-scooters. The start-up company is pursuing an aggressive EV expansion strategy growing in the United States, Europe and Southeast Asia. VinFast officially signed agreements with 12 new dealers... Read the Full Story |
|
Consumer Discretionary | |
Plant-based meat producer Beyond Meat Inc. (NASDAQ: BYND) has a 39.81% short interest. Sentiment is negative for the stock as it continues to fall lower, trading down more than 25% year-to-date (YTD). The stock recently provided investors with a fleeting lifeline, briefly jumping to $10.31 on a sh... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. | | View Today's Stock Pick |
|
